
MAIA Biotechnology, Inc.: updates and filings
Price
$1.11
November 20, 2026Market cap $67M
What Ploutos Investor adds for MAIA Biotechnology
Part of Ploutos Investor, €9.99 a month
- The full history: 4 fiscal years, from 2022
- The estimated fair value, with its range and its certainty
- The full analysis, 18 a month
- More questions to the chat on its filings
- Excel with every year
- An email when it reports, changes its dividend or an officer buys
Sign in with a free account to see the last 5 fiscal years.
What comes next, and what happened
Its next results and latest dividend, and the filings that told of something: results, deals, people, debt. In plain words, each linked to the filing.
May 2026
April 2026
Its SEC filings
What it has filed lately, newest first, linked to the document itself.
- Nov 17, 2026Regulation FD disclosureForm8-K
- Nov 9, 2026Quarterly reportfor the period to Sep 30, 2026Form10-Q
- Oct 6, 2026FilingFormEFFECT
- Oct 6, 2026Regulation FD disclosureForm8-K
- Sep 25, 2026Shelf registration for future offeringsFormS-3
- Aug 28, 2026FilingFormEFFECT
- Aug 21, 2026Shelf registration for future offeringsFormS-3
- Aug 14, 2026Over-5% holder statement (passive) (amendment)FormSCHEDULE 13G/A
- Aug 10, 2026Quarterly reportfor the period to Jun 30, 2026Form10-Q
- May 22, 2026Shareholder voteForm8-K
- May 19, 2026Additional annual meeting materialFormDEFA14A
- May 15, 2026Over-5% holder statement (passive)FormSCHEDULE 13G
- May 14, 2026Material agreement endedForm8-K
- May 11, 2026Quarterly reportfor the period to Mar 31, 2026Form10-Q
- Apr 27, 2026Additional annual meeting materialFormDEFA14A
- Apr 16, 2026Other material eventsForm8-K
- Apr 8, 2026Other material eventsForm8-K
- Apr 7, 2026Shares registered for employeesFormS-8
- Apr 7, 2026Annual report to shareholdersfor the period to Dec 31, 2025FormARS
- Apr 7, 2026Additional annual meeting materialFormDEFA14A
- Apr 7, 2026Annual meeting proxy statementFormDEF 14A
- Apr 2, 2026Officer or director changeForm8-K
- Mar 31, 2026Other material eventsForm8-K
- Mar 27, 2026Regulation FD disclosure, other material eventsForm8-K
- Mar 23, 2026Annual reportfor the period to Dec 31, 2025Form10-K
| Filed | Form | What it is | Filing |
|---|---|---|---|
| Nov 17, 2026 | 8-K | Regulation FD disclosure | Document |
| Nov 9, 2026 | 10-Q | Quarterly reportfor the period to Sep 30, 2026 | Document |
| Oct 6, 2026 | EFFECT | Filing | Document |
| Oct 6, 2026 | 8-K | Regulation FD disclosure | Document |
| Sep 25, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 28, 2026 | EFFECT | Filing | Document |
| Aug 21, 2026 | S-3 | Shelf registration for future offerings | Document |
| Aug 14, 2026 | SCHEDULE 13G/A | Over-5% holder statement (passive) (amendment) | Document |
| Aug 10, 2026 | 10-Q | Quarterly reportfor the period to Jun 30, 2026 | Document |
| May 22, 2026 | 8-K | Shareholder vote | Document |
| May 19, 2026 | DEFA14A | Additional annual meeting material | Document |
| May 15, 2026 | SCHEDULE 13G | Over-5% holder statement (passive) | Document |
| May 14, 2026 | 8-K | Material agreement ended | Document |
| May 11, 2026 | 10-Q | Quarterly reportfor the period to Mar 31, 2026 | Document |
| Apr 27, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 16, 2026 | 8-K | Other material events | Document |
| Apr 8, 2026 | 8-K | Other material events | Document |
| Apr 7, 2026 | S-8 | Shares registered for employees | Document |
| Apr 7, 2026 | ARS | Annual report to shareholdersfor the period to Dec 31, 2025 | Document |
| Apr 7, 2026 | DEFA14A | Additional annual meeting material | Document |
| Apr 7, 2026 | DEF 14A | Annual meeting proxy statement | Document |
| Apr 2, 2026 | 8-K | Officer or director change | Document |
| Mar 31, 2026 | 8-K | Other material events | Document |
| Mar 27, 2026 | 8-K | Regulation FD disclosure, other material events | Document |
| Mar 23, 2026 | 10-K | Annual reportfor the period to Dec 31, 2025 | Document |
From the company's record at the SEC (EDGAR). The topics of each 8-K are the item codes the company itself filed. Its whole record at the SEC, since Oct 15, 2021.
The full analysis
What do MAIA Biotechnology's filings show?
The filings are where every one of MAIA Biotechnology's figures comes from. The full Ploutos AI analysis reads everything the company has filed and shows what stands behind it, with a source for every figure.
- A fair value range built from the filings
- Earnings quality, debt and red flags
- Insider and institutional moves
- The case for and the case against
Related pages
The other pages on US stocks, free to read. On the company pages, the last three fiscal years are open to everyone, five with a free account, and every year with Ploutos Investor.
The figures come from the company's SEC filings and the share price, and describe what it has reported. They are not a score or a fair value.